Eli Lilly’s New Drug Mounjaro Launched on January 2, Approved for Two Indications

Eli Lilly announced on January 2 that its innovative drug Mounjaro (tirzepatide injection) has officially launched in the Chinese market and has received approval for two indications. The drug is suitable for the following two categories of adult patients: first, those with type 2 diabetes who, despite receiving treatment with metformin and/or sulfonylureas, still have unsatisfactory blood sugar control based on diet control and exercise; second, those who, based on diet control and increased exercise, have an initial Body Mass Index (BMI) of 28 kg/m² (obese) or 24 kg/m² (overweight) and have at least one weight-related comorbidity (such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, cardiovascular disease, etc.) for long-term weight management.

In addition, Eli Lilly has submitted a request to the court to join the lawsuit opposing the compound pharmacy's action against the U.S. Food and Drug Administration (FDA). Previously, the FDA determined that Eli Lilly's key drug components were no longer facing supply shortages. Eli Lilly stated that it decided to join the lawsuit because it could not ensure the FDA would adequately represent its interests in this case. The lawsuit involves cheaper versions of Eli Lilly's weight loss drug Zepbound and diabetes drug Mounjaro, both of which contain the same active ingredient, tirzepatide. The FDA announced in October that the supply shortage issue for tirzepatide has been resolved.